Nal-IRI

nanoliposomal irinotecan · Ipsen

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Nal-IRI, covering 2017-01-11 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer [Phase 2]

See pricing